Chenguang Biotech Group Co., Ltd. Class A

Chenguang Biotech Group Co., Ltd. Class A

SSZSE:300138
12.49
CNY
+0.09
(+0.73%)
0.71EPS
16.05P/E
5.39BMarket Cap
Mar 30Next Earn
Chenguang Biotech Group Co., Ltd. Class A
SZSE:300138
(Shenzhen Stock Exchange)

Recent

price

12.49

P/E

ratio

16.05

div

yld

4.14%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.76
2.54
2.25
2.81
2.86
3
4.2
5.43
5.97
6.36
8.1
9.22
11.82
12.92
13.52
13.58
13.55
Revenue per Share
0.19
0.18
0.14
0.02
0.05
0.16
0.18
0.28
0.28
0.38
0.55
0.67
0.81
0.9
0.18
0.76
0.69
Basic EPS, GAAP
-0.87
-0.24
-0.66
-0.27
0.56
-0.33
-0.82
-0.54
-0.38
-0.56
0.19
-0.41
1.05
-1.46
-0.72
0.16
- -
Free Cash Flow per Basic Share
0.03
0.05
0.07
0.09
0.05
0.04
0.05
0.08
0.15
0.2
0.19
0.21
0.27
0.34
0.34
0.33
0.52
Dividend per Share
2.14
2.26
2.36
2.34
2.38
3.35
2.93
3.16
3.4
3.42
3.97
5.23
5.94
6.51
6.44
7.02
7.08
Book Value per Share
2.05
2.11
2.16
2.12
2.16
3.08
2.7
2.93
3.15
3.13
3.47
4.72
5.35
5.92
5.72
6.34
6.42
Tangible Book Value per Share
332
422
422
423
422
422
509
511
513
514
483
529
533
532
517
483
483
Basic Weighted Avg Shares
584
1,071
951
1,186
1,207
1,268
2,141
2,772
3,063
3,265
3,913
4,874
6,296
6,872
6,994
6,559
6,543
Sales/Revenue/Turnover
13.33
8.32
5.4
3.9
3.28
4.82
5.29
6.15
6.19
8.04
10.16
8.8
8.06
7.56
3.71
7.32
7.49
Operating Margin (%)
14
20
35
44
46
47
50
57
76
89
112
131
145
153
167
184
- -
Depreciation Expense
64
75
59
10
22
69
92
143
145
194
268
352
434
480
94
369
335
Net Income, GAAP
10.24
15.72
8.94
38.96
29.15
13.72
12.82
15.78
5.66
9.84
14.87
11.92
13.09
11.09
27.11
14.39
12.91
Effective Tax Rate (%)
10.88
7
6.19
0.88
1.85
5.43
4.32
5.15
4.74
5.93
6.84
7.21
6.89
6.98
1.34
5.62
5.13
Profit Margin (%)
711
575
464
420
460
841
853
828
783
759
1,486
1,295
2,170
2,415
2,213
1,649
1,640
Working Capital
3
- -
- -
- -
- -
- -
- -
- -
- -
258
1,031
306
774
869
1,071
51
73
LT Debt
933
969
998
990
1,009
1,427
1,525
1,624
1,740
1,741
2,060
2,783
3,214
3,532
3,155
3,439
3,479
Total Equity
8
6.17
3.21
0.51
0.59
3.21
4.29
4.67
4.77
5.25
6.54
7.21
7.46
7.01
0.97
4.48
- -
Return on Invested Capital (%)
8.88
7.68
5.88
1.64
2.74
5.36
5.03
7.46
6.9
7.36
8.32
8.53
8.69
7.81
2.44
5.29
- -
Return on Capital (%)
11.62
8.07
6.04
1.06
2.24
5.68
6.33
9.13
8.62
11.09
14.05
14.5
14.59
14.46
2.86
11.35
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6,567
5,271
4,358
LT Borrowings
45
45
72
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
483
483
483
Market Capitalization
5,846
4,348
5,387

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
9,032
7,541
6,757
Cash, Cash Equivalents & STI
3,391
2,874
3,274
Accounts Receivable, Net
473
457
533
Inventories
3,982
3,237
2,270
Total Current Liabilities
7,293
5,885
5,118
Payables & Accruals
- -
- -
- -
ST Debt
6,567
5,271
4,358
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.77%
11.77%
9.01%
Free Cash Flow
-105.05%
-220.83%
-120.85%
Net Income, GAAP
43.91%
55.42%
292.21%
Sales/Revenue/Turnover
19.38%
11.69%
-6.22%
Total Cash Common Dividend
28.71%
12.38%
-8.16%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,732
1,759
1,734
1,769
6,994
2025
1,716
1,941
- -
1,512
6,559
2026
1,629
1,530
1,872
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.12
-0.08
0.07
0.18
2025
0.23
0.22
- -
0.13
0.76
2026
0.2
0.17
0.19
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.2
0.05
0.05
0.34
2025
0.05
0.21
- -
0.04
0.33
2026
0.07
0.36
0.04
- -
- -
Business
ChenGuang Biotech Group Co., Ltd. ChenGuang Biotech Group Co., Ltd. (300138.SZ) is a China-based high-tech enterprise primarily engaged in the research, development, production, and sale of natural plant extracts, utilizing agricultural products as raw materials to extract, separate, purify, and apply active plant ingredients for use in food, cosmetics, baking, beverages, health products, pharmaceuticals, and animal feed industries. The company offers six main product series encompassing over 100 items, including natural colors such as paprika oleoresin, capsicum oleoresin, marigold oleoresin, lutein, lycopene, zeaxanthin, astaxanthin, and curcumin; spice extracts and essential oils like Sichuan pepper oil, black pepper oleoresin, ginger extract, and cumin seed oil; nutritional and health extracts including grape seed extract, green coffee bean extract, milk thistle extract, and inulin; natural sweeteners such as steviosides; rare oils like cottonseed oil, flaxseed oil, safflower seed oil, grape seed oil, and walnut oil; and animal feed products featuring dephenolized cottonseed protein. Founded in 2000 and headquartered at No. 1 Chenguang Road, Quzhou County, Handan City, Hebei Province, China, ChenGuang Biotech Group operates subsidiaries and production facilities in China, India, Zambia, Myanmar, and the United States, with raw material sourcing from regions including Xinjiang Province in China, Andhra Pradesh in India, Africa, and overseas farms, exporting to Europe, the Americas, Australia, Russia, Japan, South Korea, Southeast Asia, and other African markets. Recent developments include technical upgrades to its protein production line boosting high-protein output, stevia extraction enhancements reducing costs, completion of a 200-ton capsicum oleoresin facility in Tengchong, commissioning of a nutrition and medicine extraction project, successful marigold trial planting in Myanmar and paprika harvests in Zambia, breakthroughs in 5-CQA conversion and silymarin processes, a 9% yield increase in lutein ester products, progress in astaxanthin technology and double haploid marigold breeding, along with robust growth in its Yingkou equipment business, surging animal health product sales, record health food revenue, and agreements to acquire the remaining 22.5% stake in Hebei Ruide Natural Pigment Co., Ltd. to consolidate pigment operations.